Synplogen

Executive Summary

Synplogen is a Japanese synthetic biology startup specializing in proprietary long-strand DNA synthesis and DNA library construction technologies. Founded in 2017 and headquartered in Kobe, the company operates a Gene Therapy Biofoundry™ that provides end-to-end design, development, and analytical services for gene therapies, including viral vectors and mRNA. By focusing on advanced DNA synthesis and CMC development, Synplogen aims to accelerate the commercialization of gene therapies. As a platform company with 10-50 employees, it serves the genetic disease and oncology segments. Despite limited public financial information and no disclosed pipelines, Synplogen's niche in DNA synthesis positions it as a potential enabler for the growing gene therapy market. The company's ability to secure partnerships and scale its technology will be key to its success.

Upcoming Catalysts (preview)

• Q2 2027Strategic Partnership with a Major Pharma Company40% success
• Q4 2026Series A Funding Round Announcement50% success
• Q1 2027Launch of New mRNA Service Offering60% success